Prenetics Global Ltd
PRE
View Detailed Chart
19.240USD
+1.530+8.64%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
248.08MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+8.64%
5 Days
+0.76%
1 Month
+18.04%
6 Months
+144.16%
Year to Date
+22.16%
1 Year
+255.64%
View Detailed Chart
TradingKey Stock Score of Prenetics Global Ltd
Currency: USD Updated: 2026-02-06Key Insights
Prenetics Global Ltd's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 84 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 31.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Prenetics Global Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Prenetics Global Ltd Highlights
StrengthsRisks
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 132.61% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 30.62M.
Undervalued
The company’s latest PE is -5.43, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.19M shares, decreasing 53.06% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 26.22K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.14.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
31.000
Target Price
+75.04%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Prenetics Global Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Prenetics Global Ltd Info
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
Ticker SymbolPRE
CompanyPrenetics Global Ltd
CEOKwok (Samantha)
Websitehttps://ir.prenetics.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69285.330
-684.800 (-0.98%)
282.580
+22.390 (+8.61%)
2053.610
+1.880 (+0.09%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
